Expanded agreement builds on the license Jocasta acquired from Unity Biotechnology

Jocasta Neuroscience, Inc., a biotechnology company developing therapeutics to address neurodegenerative diseases, today announced it has entered into a new licensing agreement with the University of California, San Francisco (UCSF) through its Innovation Ventures office to develop α-klotho-based therapies aimed at enhancing cognitive function. The agreement supersedes and expands the license Jocasta previously acquired from Unity Biotechnology.

Press Release